Complete response of melanoma-in-transit metastasis after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: a clinical and histopathological study of the delayed-type reaction pattern.
P T Nooijen(Radboud University Nijmegen), D. J. Ruiter(Radboud University Nijmegen), Alexander M.M. Eggermont(University Medical Center Utrecht), Lia Schalkwijk, S.C. Henzen‐Logmans(Rotterdam University of Applied Sciences), R M de Waal
PubMed
November 1, 1998
Cited by 38
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k